The global nasal drug delivery market was valued at USD 42.39 billion in 2018 and is expected to grow to USD 120.83 billion by 2032, reflecting a CAGR of 7.9% over the forecast period. In 2018, Europe led the market, accounting for 49.82% of the global share.
Nasal drug delivery has emerged as a prominent area of research, leading to the development of compact, portable, and user-friendly devices through advanced technologies. The nasal route is favored for drug administration due to its rapid onset of action, enhancing the treatment of various conditions. Recent efforts have focused on delivering biotherapeutics, including polypeptides, peptides, and antisense DNA, via the nasal pathway, offering a non-invasive alternative to traditional injection methods. These advancements are poised to significantly drive the expansion of the nasal drug delivery market.
Market Segmentation:
Dry Powder Inhalers (DPIs) Leading the Market
The nasal drug delivery market encompasses various devices, including Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), and nebulizers. DPIs currently hold the largest market share, attributed to their product stability, flexible dosing options, and low susceptibility to microbial contamination. MDIs follow in market share but present challenges due to their complex usage steps, which can lead to user errors. Nebulizers occupy a smaller portion of the market, primarily utilized within hospital settings. Ongoing efforts to develop more user-friendly DPIs are anticipated to further propel market growth.
Chronic Obstructive Pulmonary Disease (COPD) Dominates Application Segment
COPD represents the largest segment within the application category of the nasal drug delivery market. According to the Centers for Disease Control and Prevention (CDC), approximately 16 million Americans are diagnosed with COPD, underscoring a substantial patient base that drives the demand for inhalers. Asthma is projected to be the fastest-growing segment, with its increasing prevalence in emerging countries contributing to this trend.
Retail Pharmacies Driving Distribution Channel Growth
In terms of distribution channels, retail pharmacies lead the market due to their accessibility and the rising demand for inhalers among patients. Hospital pharmacies follow, supported by an increase in hospital admissions related to asthma and COPD. The convenience and widespread presence of retail pharmacies make them a preferred choice for patients seeking nasal drug delivery devices.
Overall, the nasal drug delivery market is experiencing significant growth, driven by advancements in inhaler technology, a growing patient population with respiratory conditions, and the accessibility of these devices through various distribution channels.
Get a Free Sample Research PDF:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nasal-drug-delivery-market-100415
Major Players Profiled in the Nasal Drug Delivery Market Report:
Consort Medical plc.
AptarGroup, Inc.
Vectura Group plc
3M
H&T Presspart Manufacturing Ltd.
Nemera
GOFIRE INC.
Teva Pharmaceutical Industries Ltd.
Others
Market Drivers:
The rising prevalence of pulmonary diseases is driving demand for nasal drug delivery devices. WHO estimates 300 million people globally suffer from asthma, all relying on inhalation for effective treatment. Industry players are introducing patient-friendly, cost-effective devices, such as Aptar Pharma’s PureHale inhaler in 2018, to enhance respiratory care. COPD-related hospital admissions, particularly in Europe, are further fueling market growth, increasing demand for DPIs and MDIs. Additionally, the expiration of patents on branded inhalers is boosting the availability of generic alternatives, reducing treatment costs and increasing adoption. For instance, Mylan’s 2019 FDA-approved generic, Wixela Inhub, offers a lower-cost alternative to Advair Diskus. Growing awareness of these inhalers is expected to further drive market expansion.
Market Restraint:
Lack of Patient Awareness on Proper Dosage Administration May Hinder Market Growth
Despite the proven efficacy of DPIs and MDIs in delivering accurate doses, many patients struggle with proper usage, leading to ineffective treatment. A key challenge is the incorrect administration of these devices, particularly among older adults due to a lack of training and understanding. Improper use can result in under-dosing, negatively impacting patient health and limiting device adoption, which may slow market growth during the forecast period.
Regional Insights:
Our research indicates that Europe will hold the largest Nasal Drug Delivery market share during the forecast period, driven by the high prevalence of COPD and asthma. The region benefits from widespread awareness of inhaler advantages, with rising cases in Ireland and other developing European nations further fueling demand. Additionally, the growing acceptance of smart inhalers is expected to contribute to regional growth.
Meanwhile, Asia Pacific is projected to experience significant growth due to increasing inhaler adoption. Governments are actively promoting awareness campaigns, while biopharma companies are leveraging novel technologies to develop DPIs and MDIs. Substantial investments in smart inhalers, along with rising disease incidences and greater patient awareness, are expected to drive market expansion in the region.
Key Industry Developments:
March 2021 – Aptar Pharma and its subsidiary, Noble, partnered with dne pharma, a leading addiction medicine company in Northern Europe. The collaboration focuses on providing nasal drug delivery expertise and training solutions for dne pharma’s Ventizolve nasal naloxone, used in opioid overdose treatment.
February 2021 – Nanoform Finland and Herantis signed a non-exclusive agreement to collaborate on nasal drug delivery to the brain, aiming to develop formulation proof-of-concept projects.